Autoimmune Diseases after Autologous Hematopoietic Stem Cell Transplantation in Patients with Non-Hodgkin's Lymphoma.
- Author:
Min Young LEE
1
;
Shi Nae YU
;
Kyoung Ha KIM
;
Sang Cheol LEE
;
Nam Su LEE
;
Hee Sook PARK
;
Jong Ho WON
Author Information
1. Division of Hematology and Oncology, Department of Internal Medicine, Soonchunhyang University College of Medicine, Seoul, Korea. jhwon@schmc.ac.kr
- Publication Type:Case Report
- Keywords:
Autoimmune diseases;
Stem cell transplantation;
Autologous;
Lymphoma, Non-Hodgkin's
- MeSH:
Autoimmune Diseases;
Autoimmunity;
Hematopoietic Stem Cell Transplantation;
Hematopoietic Stem Cells;
Humans;
Immune System;
Lymphoma, Non-Hodgkin;
Stem Cell Transplantation
- From:Korean Journal of Medicine
2013;85(4):430-434
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Autologous hematopoietic stem cell transplantation (HSCT) is an effective treatment for patients with relapsed or high-risk Non-Hodgkin's lymphoma (NHL). HSCT fundamentally interferes with the immune system. As a consequence, development of autoimmunity after HSCT has been observed during the past several decades. Most evidence is derived from single case reports or studies on small series of patients who developed novel-onset autoimmune diseases after use of HSCT to treat various conditions. We treated 3 NHL patients with autoimmune disease among 54 NHL patients who received high-dose chemotherapy and autologous HSCT.
